Professor Chris Reutelingsperger

Since 2016, Annexin has a professional collaboration with Professor Chris Reutelingsperger. Prof. Reutelingsperger advises Annexin on future research and product opportunities for the company’s drug candidate ANXV.

Prof. Chris Reutelingsperger studied Biochemistry at the University of Utrecht. As a PhD student, he discovered the anticoagulant annexin A5 (Vascular Anticoagulant) and defended the thesis ‘Vascular anticoagulant, a novel anticoagulant mechanism’ at Maastricht University in 1987. He was awarded the five-year Senior Fellowship of the Royal Dutch Academy of Sciences (KNAW) and spent part of his post-doc time at the Boehringer Ingelheim Institute für Arzneimittelforschung in Vienna, to work on elucidating the genetic code of Annexin A5.

In 1994, he discovered and patented the ability of Annexin A5 to detect apoptotic cells. In 1992, he received a tenure track at the Department of Biochemistry of Maastricht University, resulting in a tenured position as Associate Professor in 1997. In 2009, he was appointed Professor of Biochemistry of Apoptosis at Maastricht University. He (co-)authored over 275 peer reviewed papers (H-index 85, source Scholar Google). He is (co-)inventor of 12 granted patents and CSO of PharmaTarget, a biotech company which he co-founded in 2006. He was the President of the 8th International Conference on Annexins in 2015. Currently, he chairs the Scientific Advisory Board of Matisse Pharmaceuticals (Netherlands), a biotech company developing therapeutic drugs to treat sepsis